Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

This study is ongoing, but not recruiting participants.

Study NCT00316849 Information provided by National Cancer Institute (NCI)

First Received: April 19, 2006 Last Updated: October 8, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	April 2008 (Final data collection date for primary outcome measure)

Publications:

Sarkaria JN, Galanis E, Wu W, Dietz AB, Kaufmann TJ, Gustafson MP, Brown PD, Uhm J, Rao RD, Doyle L, Giannini C, Jaeckle K, Buckner JC. Combination of temsirolimus (CCI-779) with chemo-radiation in newly diagnosed GBM (NCCTG trial N027D) is associated with increased infectious risks. Clin Cancer Res. 2010 Oct 4; [Epub ahead of print]

Sarkaria JN, Galanis E, Wu W, et al.: NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients. [Abstract] J Clin Oncol 27 (Suppl 15): A-2019, 2009.